

***Pseudomonas aeruginosa*, Strain P179**

Catalog No. NR-31041

For research use only. Not for human use.

Contributor:

George A. Jacoby, M.D., Infectious Disease Department, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA

Manufacturer:

BEI Resources

Product Description:

Bacteria Classification: *Pseudomonadaceae*, *Pseudomonas*
Species: *Pseudomonas aeruginosa* (NR-31041 was deposited to BEI Resources as *Pseudomonas* sp., however, digital DNA-DNA hybridization (dDDH) testing, performed at BEI Resources, resulted in its classification to *Pseudomonas aeruginosa*.)

Strain: P179

Original Source: *Pseudomonas aeruginosa* (*P. aeruginosa*), strain P179 was isolated in or before 1983 from a human subject in Cincinnati, Ohio, USA.^{1,2}

Comments: *P. aeruginosa*, strain P179 ([HMP ID 1224](#)) was deposited as resistant to gentamicin, streptomycin and sulfonamides.¹⁻³ Strain P179 contains IncP-2 plasmid pMG43, responsible for antibiotic and metal ion (borate, mercuric chloride, phenylmercuric acetate, tellurate and tellurite) resistance.^{1,2} *P. aeruginosa*, strain P179 is a reference genome for [The Human Microbiome Project](#) (HMP). HMP is an initiative to identify and characterize human microbial flora. The complete genome of *P. aeruginosa*, strain P179 has been sequenced (GenBank: [AQFN00000000](#)).

P. aeruginosa is a Gram-negative, aerobic, rod-shaped bacterium with unipolar motility that thrives in many diverse environments including soil, water, and certain eukaryotic hosts. It is a key emerging opportunistic pathogen in animals, including humans, and plants. While it rarely infects healthy individuals, *P. aeruginosa* causes severe acute and chronic nosocomial infections in immunocompromised or catheterized patients, especially in patients with cystic fibrosis, burns, cancer or HIV.⁴⁻⁶ Infections of this type are often highly antibiotic resistant, difficult to eradicate, and often lead to death. The ability of *P. aeruginosa* to survive on minimal nutritional requirements, tolerate a variety of physical conditions, and rapidly develop resistance during the course of therapy has allowed it to persist in both community and hospital settings.^{6,7}

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in Nutrient broth supplemented with 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-31041 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:

Tryptic Soy broth or Brain Heart Infusion broth or Nutrient broth or equivalent

Tryptic Soy agar with 5% defibrinated sheep blood or Brain Heart Infusion agar or Nutrient agar or equivalent

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tube, slant and/or plate at 37°C for 1 day.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: *Pseudomonas aeruginosa*, Strain P179, NR-31041.”

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#), 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

1. Jacoby, G. A., Personal Communication.
2. Jacoby, G. A., et. al. "Properties of IncP-2 Plasmids of *Pseudomonas* spp." Antimicrob. Agents Chemother. 24 (1983): 168-175. PubMed: 6638986.
3. [HMP ID 1224](#) (*Pseudomonas* sp., Strain P179)
4. Silva Filho, L. V., et al. "*Pseudomonas aeruginosa* Infection in Patients with Cystic Fibrosis: Scientific Evidence Regarding Clinical Impact, Diagnosis, and Treatment." J. Bras. Pneumol. 39 (2013): 495-512. PubMed: 24068273.
5. Dettman, J. R., et al. "Evolutionary Genomics of Epidemic and Nonepidemic Strains of *Pseudomonas aeruginosa*." Proc. Natl. Acad. Sci. USA 110 (2013): 21065-21070. PubMed: 24324153.
6. Morita, Y., J. Tomida and Y. Kawamura. "Responses of *Pseudomonas aeruginosa* to Antimicrobials." Front. Microbiol. 4 (2014): 422. PubMed: 24409175.
7. Lister, P. D., D. J. Wolter and N. D. Hanson. "Antibacterial-Resistant *Pseudomonas aeruginosa*: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms." Clin. Microbiol. Rev. 22 (2009): 582-610. PubMed: 19822890.

ATCC® is a trademark of the American Type Culture Collection.

